Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

modified interleukin-2 LTC004

A modified form of the recombinant form of human endogenous cytokine interleukin-2 (IL-2), with potential immunoregulatory and antineoplastic activities. Upon injection of modified IL-2 LTC004, IL-2 binds to the IL-2 receptor beta (CD122) and gamma (CD132) subunits (IL2Rb/g) that are expressed on CD8+ T effector cells and natural killer (NK) cells, thereby activating IL2R-mediated signaling within these immune cells. The activation of T- and NK cells mediates cytolytic immune responses against tumor cells causing tumor cell destruction and inhibition of tumor cell proliferation. The additional disulfide bonds in LTC004 reduces binding of IL-2 to IL-2 receptor alpha (IL2Ralpha; IL-2Ra) and thereby reduces IL-2Ra-mediated toxicities.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:modified IL-2 LTC004
Code name:LTC 004
LTC-004
LTC004
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search